This study aims to explore the relationship between HER2 amplification in CRC cases with varying clinicopathological factors and prognosis and gene mutations, tumor-infiltrating leukocytes, TLSs, and PD-L1 protein expression. The gene discussed is ERBB2; the disease is neoplasm.